SG164384A1 - Novel heterocyclic compound or salt thereof and intermediate thereof - Google Patents

Novel heterocyclic compound or salt thereof and intermediate thereof

Info

Publication number
SG164384A1
SG164384A1 SG201005338-7A SG2010053387A SG164384A1 SG 164384 A1 SG164384 A1 SG 164384A1 SG 2010053387 A SG2010053387 A SG 2010053387A SG 164384 A1 SG164384 A1 SG 164384A1
Authority
SG
Singapore
Prior art keywords
salt
substituted
heterocyclic compound
novel heterocyclic
bond
Prior art date
Application number
SG201005338-7A
Other languages
English (en)
Inventor
Taro Kiyoto
Junichi Ando
Tadashi Tanaka
Yasuhiro Tsutsui
Mai Yokotani
Toshiya Noguchi
Fumihito Ushiyama
Hiroki Urabe
Hiromasa Horikiri
Original Assignee
Toyama Chemical Co Ltd
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd, Taisho Pharmaceutical Co Ltd filed Critical Toyama Chemical Co Ltd
Publication of SG164384A1 publication Critical patent/SG164384A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG201005338-7A 2006-05-26 2007-05-24 Novel heterocyclic compound or salt thereof and intermediate thereof SG164384A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006146588 2006-05-26

Publications (1)

Publication Number Publication Date
SG164384A1 true SG164384A1 (en) 2010-09-29

Family

ID=38778494

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201005338-7A SG164384A1 (en) 2006-05-26 2007-05-24 Novel heterocyclic compound or salt thereof and intermediate thereof

Country Status (18)

Country Link
US (2) US8211908B2 (ja)
EP (1) EP2022793B1 (ja)
JP (1) JP5171618B2 (ja)
KR (1) KR101409261B1 (ja)
CN (1) CN101454319B (ja)
AU (1) AU2007268749B2 (ja)
BR (1) BRPI0712163A2 (ja)
CA (1) CA2652501C (ja)
ES (1) ES2476423T3 (ja)
HK (1) HK1133874A1 (ja)
IL (1) IL195346A (ja)
MX (1) MX2008014908A (ja)
NO (1) NO20084701L (ja)
NZ (1) NZ573032A (ja)
RU (1) RU2434868C2 (ja)
SG (1) SG164384A1 (ja)
WO (1) WO2007138974A1 (ja)
ZA (1) ZA200809782B (ja)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP5398984B2 (ja) 2005-06-24 2014-01-29 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
DK1954697T3 (da) * 2005-10-21 2010-06-14 Glaxo Group Ltd Peri-kondenserede tricykliske forbindelser, der er anvendelige som antibakterielle midler
WO2007138974A1 (ja) 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. 新規な複素環化合物またはその塩ならびにその中間体
NZ573644A (en) * 2006-07-20 2011-09-30 Glaxo Group Ltd Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
US20100144717A1 (en) * 2006-12-15 2010-06-10 Janelle Comita-Prevoir 2-quinolinone and 2-quinoxalinone-derivatives and their use as antibacterial agents
TW200831517A (en) * 2006-12-15 2008-08-01 Astrazeneca Ab Chemical compounds
WO2008071964A1 (en) * 2006-12-15 2008-06-19 Astrazeneca Ab Naphthyridine bactericides
WO2008071962A1 (en) * 2006-12-15 2008-06-19 Astrazeneca Ab Pteridines and pyrimidinopyridines as antibacterial agents
CN101874032B (zh) 2007-11-26 2013-02-06 富山化学工业株式会社 二氮杂萘衍生物一水合物及其制备方法
JP5620636B2 (ja) * 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
EP2080761A1 (en) * 2008-01-18 2009-07-22 Glaxo Group Limited Compounds
CA2713187C (en) 2008-02-22 2016-06-07 Actelion Pharmaceuticals Ltd Oxazolidinone derivatives
WO2009147616A1 (en) 2008-06-03 2009-12-10 Actelion Pharmaceuticals Ltd [4-(1-amino-ethyl) -cyclohexyl] -methyl-amine and [6-(1-amino-ethyl) -tetrahydro- pyran-3-yl] -methyl-amine derivatives as antibacterials
US20110172217A1 (en) * 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
ES2628091T3 (es) 2008-10-10 2017-08-01 Idorsia Pharmaceuticals Ltd Antibióticos de oxazolidinilo
TW201022279A (en) * 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
CA2740863A1 (en) 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids
ES2561631T3 (es) * 2009-01-15 2016-02-29 Glaxo Group Limited Compuestos de naftiridin-2(1H)-ona útiles como agentes antibacterianos
CN102341133A (zh) * 2009-02-02 2012-02-01 麦德托尼克公司 植入式医疗器械的抗菌配件
AR076222A1 (es) * 2009-04-09 2011-05-26 Actelion Pharmaceuticals Ltd Derivados 2-hidroxietil-1h-quinolin-ona y sus analogos azaisotericos con actividad antibacteriana y composiciones farmaceuticas que los contienen
US8858983B2 (en) * 2009-04-30 2014-10-14 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
JP5685589B2 (ja) * 2010-05-25 2015-03-18 大正製薬株式会社 新規な複素環化合物又はその塩
US8911427B2 (en) 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
JPWO2012108376A1 (ja) 2011-02-07 2014-07-03 第一三共株式会社 アミノ基含有ピロリジノン誘導体
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
CN103958525A (zh) 2011-11-30 2014-07-30 埃科特莱茵药品有限公司 3,7-二取代八氢-2H-吡啶并[4,3-e][1,3]噁嗪-2-酮抗生素
EP2968331B1 (en) * 2013-03-14 2020-07-01 Icahn School of Medicine at Mount Sinai Pyrimidine compounds as kinase inhibitors
TW201722965A (zh) 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物
US11091497B2 (en) 2017-12-08 2021-08-17 The Rockefeller University Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation
CN111757879A (zh) * 2018-01-29 2020-10-09 卡地拉健康护理有限公司 用作抗菌剂的杂环化合物
CN109678793B (zh) * 2019-01-12 2020-08-04 上海卡洛化学有限公司 一种5-氟-3-氨基吡啶的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4103257A (en) 1976-05-25 1978-07-25 The United States Of America As Represented By The United States Department Of Energy Azaquinolone dye lasers
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
WO1999007682A1 (fr) 1997-08-08 1999-02-18 Toyama Chemical Co., Ltd. Derives d'acide quinolonecarboxylique ou sels de ces derives
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
US6696565B2 (en) * 2001-01-17 2004-02-24 Purdue Research Foundation Method and associated pyrimido[4,5-d]pyrimidine-2,5-diones and pyrido[4,3-d]pyrimidin-2-ones for forming nanotubes
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
TW200406413A (en) * 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
AR040336A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
JP2006511554A (ja) 2002-12-13 2006-04-06 スミスクライン ビーチャム コーポレーション Ｃｃｒ５アンタゴニストとしてのピペリジン誘導体
BRPI0507628A (pt) * 2004-02-11 2007-07-03 Smithkline Beecham Corp composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
US20070254872A1 (en) 2004-07-08 2007-11-01 Glaxo Group Limited Antibacterial Agents
EP1778688A1 (en) * 2004-07-22 2007-05-02 Glaxo Group Limited Antibacterial agents
EP1781669B1 (en) * 2004-08-02 2010-10-13 Glaxo Group Limited Antibacterial agents
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
AU2006250987A1 (en) 2005-05-24 2006-11-30 Astrazeneca Ab Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
JP5398984B2 (ja) 2005-06-24 2014-01-29 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
WO2007138974A1 (ja) 2006-05-26 2007-12-06 Toyama Chemical Co., Ltd. 新規な複素環化合物またはその塩ならびにその中間体
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
WO2008071962A1 (en) 2006-12-15 2008-06-19 Astrazeneca Ab Pteridines and pyrimidinopyridines as antibacterial agents
WO2008071964A1 (en) 2006-12-15 2008-06-19 Astrazeneca Ab Naphthyridine bactericides
WO2009001126A1 (en) 2007-06-27 2008-12-31 Astrazeneca Ab Substituted piperidine derivatives and their use as antibaterial agents
CN101874032B (zh) 2007-11-26 2013-02-06 富山化学工业株式会社 二氮杂萘衍生物一水合物及其制备方法

Also Published As

Publication number Publication date
US20090198063A1 (en) 2009-08-06
WO2007138974A1 (ja) 2007-12-06
KR20090018976A (ko) 2009-02-24
NZ573032A (en) 2010-12-24
BRPI0712163A2 (pt) 2012-03-13
US20120226035A1 (en) 2012-09-06
MX2008014908A (es) 2009-05-13
JPWO2007138974A1 (ja) 2009-10-08
RU2434868C2 (ru) 2011-11-27
IL195346A0 (en) 2009-08-03
RU2008151754A (ru) 2010-07-10
KR101409261B1 (ko) 2014-06-18
EP2022793A1 (en) 2009-02-11
AU2007268749B2 (en) 2012-07-26
JP5171618B2 (ja) 2013-03-27
AU2007268749A1 (en) 2007-12-06
HK1133874A1 (en) 2010-04-09
US8367831B2 (en) 2013-02-05
CA2652501A1 (en) 2007-12-06
IL195346A (en) 2013-02-28
CA2652501C (en) 2014-07-08
CN101454319A (zh) 2009-06-10
NO20084701L (no) 2009-02-06
CN101454319B (zh) 2012-06-27
EP2022793B1 (en) 2014-06-04
ZA200809782B (en) 2010-02-24
EP2022793A4 (en) 2010-09-08
ES2476423T3 (es) 2014-07-14
US8211908B2 (en) 2012-07-03

Similar Documents

Publication Publication Date Title
SG164384A1 (en) Novel heterocyclic compound or salt thereof and intermediate thereof
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2008108380A3 (en) Pyrrole compounds
EP1852434A4 (en) BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY
MX344669B (es) Agente antiplaquetas novedoso.
MY153720A (en) Oxazole compound and pharmaceutical composition
EA017861B9 (ru) Способ получения 4-оксохинолинового соединения
TW200720252A (en) Cyclic amine derivative having substituted alkyl group
WO2009016841A1 (ja) オキソピラジン誘導体及び除草剤
WO2007106192A3 (en) Inhibitors of iap
WO2009020140A1 (ja) アダマンチルウレア誘導体
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2011004162A3 (en) 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
TW200612920A (en) Novel imidazolidine derivatives
WO2009072581A1 (ja) ラクタム化合物又はその塩及びｐｐａｒ活性化剤
WO2006113552A8 (en) Cyanoarylamines
EP1593667A4 (en) AMINE DERIVATIVE
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
TW200637539A (en) CTGF inhibitors
MX2009008756A (es) Compuesto macrociclico.
MX2010001566A (es) Derivado de aminopirazolamida.
MY136824A (en) Substituted benzoxazinones and uses thereof
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
SI1845780T1 (sl) Uporaba derivatov metilfenidata
WO2009016954A1 (ja) 水性金属加工油剤